Healthcare - Press Releases

MINNEAPOLIS, Feb. 19, 2025 /PRNewswire/ -- TheAmerican Academy of Neurology (AAN) has developed a new systematic review to summarize for neurologists and other clinicians the evidence for epidural steroid injections and whether they reduce pain and disability for people with certain kinds of chronic back pain. The systematic review is published in the February 12, 2025, online issue of Neurology. It updates a 2007 assessment by the AAN.

New PSA highlights the impacts of Adverse Childhood Experiences (ACEs) and toxic stress, offering tools to help Californians heal and build resilience

SAN MATEO, Calif., Feb. 19, 2025 /PRNewswire/ --Peninsula Family Service (PFS), a leading nonprofit organization dedicated to empowering individuals and families across the Peninsula, is proud to announce a year-long celebration marking its 75th anniversary. Since 1950, PFS has been a trusted community partner, providing essential services that enable community members to lead healthy, stable lives.

CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I), today announced a licensing agreement with the University of Alabama at Birmingham (UAB) to support their research in B cell development.

CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- OpenEvidence, the fastest-growing platform for doctors in history, has closed a Series A with Sequoia Capital at a $1 billion valuation. This milestone marks OpenEvidence's first institutional investment and brings the company's total capital raised to over $100 million.

TAIPEI, Feb. 19, 2025 /PRNewswire/ -- NaviFUS Corp. is dedicated to advancing non-invasive treatments for complex brain disorders, a challenging area in medical innovation. By using ultrasound technology for both diagnosis and therapy, NaviFUS exceeds the signal processing capabilities of traditional medical devices. This is made possible by Taiwan's advanced chip technology, which positions NaviFUS as a global leader in focused ultrasound-based treatment solutions. This cutting-edge technology integrates ICT capabilities into high-end medical devices seamlessly.

TAIPEI, Feb. 20, 2025 /PRNewswire/ -- NaviFUS Corp. is revolutionizing brain disorder treatments through ultrasound-based solutions, leveraging Taiwan's advanced chip technology. By integrating ICT capabilities into high-end medical devices, NaviFUS enhances signal processing beyond traditional medical devices, positioning itself as a global leader in focused ultrasound treatments.

TAIPEI, 20 fvrier 2025 /PRNewswire/ -- NaviFUS Corp. rvolutionne les traitements des troubles crbraux grce des solutions bases sur les ultrasons, en tirant parti de la technologie avance des puces de Tawan. En intgrant des capacits TIC dans des appareils mdicaux haut de gamme, NaviFUS amliore le traitement des signaux au-del des appareils mdicaux traditionnels, se positionnant ainsi comme un leader mondial dans les traitements par ultrasons focaliss.

TAIPEI, 20. Februar 2025 /PRNewswire/ -- NaviFUS Corp. revolutioniert die Behandlung von Hirnleistungsstrungen durch ultraschallbasierte Lsungen und nutzt dabei die fortschrittliche Chiptechnologie Taiwans. Durch die Integration von IKT-Funktionen in medizinische High-End-Gerte verbessert NaviFUS die Signalverarbeitung ber die herkmmlichen medizinischen Gerte hinaus und positioniert sich als weltweit fhrendes Unternehmen fr fokussierte Ultraschallbehandlungen.

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-A) antibody program to Bristol Myers Squibb.Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-A) antibody program to Bristol Myers Squibb.Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli (pegcetacoplan) for the treatmentof C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.

SOUL, Core du Sud, 20 fvrier 2025 /PRNewswire/ -- Coway Co. Ltd, la Best Life Solution Company, a officiellement lanc son plan d'amlioration de la valeur de l'entreprise, raffirmant son engagement en faveur de l'amlioration durable de la valeur actionnariale. Aprs avoir annonc le mois dernier l'augmentation de son taux de rendement total pour l'actionnaire de 20% 40%, Coway lance prsent des initiatives stratgiques supplmentaires visant renforcer la valeur de l'entreprise.

SEOUL, Zuid-Korea, 20 februari 2025 /PRNewswire/ -- Coway Co., Ltd., de "Best Life Solution Company", heeft officieel zijn "Corporate Value-Up Plan" gelanceerd, waarmee het bedrijf zijn inzet voor een duurzame verbetering van de aandeelhouderswaarde opnieuw bevestigt. Na de aankondiging vorige maand om het totale aandeelhoudersrendement te verhogen van 20% naar 40%, introduceert Coway nu aanvullende strategische initiatieven gericht op het vermeerderen van de bedrijfswaarde.

BRUSSELS, Feb. 20, 2025 /PRNewswire/ --Mars, Incorporated - the leading pet care business - has announced the launch of the Pets and Wellbeing Study (PAWS) program. PAWS is set to become the world's largest, multi-year research program exploring the impact of cats and dogs on mental health and wellbeing, deepening our understanding of the mutual benefits of the human-animal bond.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

BEIJING, Feb. 20, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop" or the "Company") (NYSE: WDH), a leading technology platform specializing in insurance and healthcare services with a positive social impact, announced its strategic integration of DeepSeek, marking a significant step forward in its AI-driven insurance ecosystem. The collaboration is poised to accelerate the Company's business growth, enabling innovative breakthroughs in the application of large-scale AI models across specialized insurance scenarios.

NASDAQ | TSX: ACB

YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the latest efficacy and safety data from the phase II clinical trial (NCT05297552, Study ID: RC48-C017) of Disitamab Vedotin (DV) in combination Toripalimab as the neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC) in an oral presentation. This marks the first public disclosure of results from a prospective clinical study investigating an ADC drug in combination with an immunotherapy as a perioperative therapy for MIBC. The pathological complete response (pCR) rate reached an impressive 63.6%, which is a breakthrough improvement compared with traditional neoadjuvant chemotherapies (36%-42%). ASCO GU is one of the top urologic oncology conferences that leading experts worldwide in this field attend.

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The globalgender reassignment surgery market size is estimated to grow by USD 374.2 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over11.2% during the forecast period. Increase in number of people opting for sex change surgeries globallyis driving market growth,with a trend towardsadvancements in medical technology. However,high cost of surgeries poses a challenge. Key market players include Andrew Ives., Boston Childrens Hospital, Boston Medical Center, Chettawut Plastic Surgery Center, CNY Cosmetic and Reconstructive Surgery, Crane Center, Icahn School of Medicine at Mount Sinai, IVAN MANERO CLINIC S.L., Moein Surgical Arts, Oregon Health and Science University, Phuket International Aesthetic Centre PIAC, Plastic Surgery Group of Rochester, Regents of the University of Michigan, Rumer Cosmetic Surgery, Sava Perovic Foundation Surgery, The Johns Hopkins Health System Corp., Transgender Surgery Institute, and University of Pennsylvania Health System.

VIRGINIA BEACH, Va., Feb. 15, 2025 /PRNewswire/ -- LifeNet Health proudly announces the launch of OraGen, the first viable dental bone allograft comprised of cryopreserved corticocancellous bone containing endogenous lineage-committedbone cells combined with demineralized bone matrix. This unique composition, the core of OraGen's innovation, delivers three essential properties for bone regeneration: osteogenicity, with lineage-committed bone cells that produce new bone; osteoconductivity, providing a biocompatible scaffold for cell attachment and growth; and osteoinduction, which stimulates bone repair through retained natural growth factors.

Bahnbrechende Technologie kombiniert rekombinantes menschliches Kollagen und Hyaluronsure fr sofortige, lang anhaltende Ergebnisse

SUN PRAIRIE, Wis., Feb. 16, 2025 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC),the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic partnership aims to enhance the capabilities and offerings for both organizations, benefiting our members and advancing independent pharmacy.

Revolutionising Vascular Access Care for Critically Ill Newborns and Children